Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > NexImmune Appoints Kenneth Carter, PhD, as President and CEO and Jonathan Schneck, MD, PhD as Chairman of Clinical and Scientific Advisory Board: Licenses Technology From The Johns Hopkins University

Abstract:
NexImmune, an early stage biopharmaceutical company, announced today the appointment of Kenneth Carter, PhD, as the company's President and Chief Executive Officer, and Professor Jonathan Schneck, MD, PhD, as Chairman of the company's Clinical and Scientific Advisory Board. At the same time, NexImmune announced that the company has licensed the Artificial IMmune (AIM™) nanotechnology for immuno-therapy, developed by Dr. Mathias Oelke and Dr. Schneck's laboratory from The Johns Hopkins University.

NexImmune Appoints Kenneth Carter, PhD, as President and CEO and Jonathan Schneck, MD, PhD as Chairman of Clinical and Scientific Advisory Board: Licenses Technology From The Johns Hopkins University

Gaithersburg, MD | Posted on January 4th, 2012

Prior to NexImmune, Dr. Carter was the President, CEO and a co-founder of Noble Life Sciences. Dr. Carter has also played a key leadership role in launching several other biotechnology companies including Avalon Pharmaceuticals, Inc. where he served as CEO for 10 years until 2009 when Avalon merged with Clinical Data, Inc. During his tenure at Avalon, the company developed a unique biomarker-based drug discovery and development engine; completed an IPO and listing on the NASDAQ market; established drug discovery programs in colon, breast, pancreatic and hematological cancers; and established partnerships with Merck, Novartis, Sanofi-Aventis, and AstraZeneca/MedImmune. Prior to Avalon, Dr. Carter directed the gene mapping initiative at Human Genome Sciences, Inc. where he played a lead role in the discovery, cloning, and chromosomal mapping of dozens of novel human genes. Dr. Carter serves on the Advisory Council for the Center for Biotechnology Education at The Johns Hopkins University where he also holds an adjunct faculty appointment.

"The AIM technology provides an exciting leap in immuno-therapy for a variety of cancer and other diseases whereby artificial cells direct specific immune responses against a specific disease. I am very pleased to lead the team that will commercialize this exciting new technology. Our first development target will be a therapeutic to treat melanoma," said Dr. Carter.

Dr. Schneck is Professor of Pathology, Medicine and Oncology at Johns Hopkins School of Medicine. He is well known for several key scientific contributions to the field including extensive work in the artificial manipulation of immune system components in order to maximize T cell responses. To facilitate the study of both normal and aberrant immune responses, he and his laboratory have developed a variety of innovative nano-molecular tools including the DimerX technology, for analysis of antigen-specific T cells, marketed by BD Biosciences, and artificial Antigen Presenting Cell (aAPC), the foundation of the AIM technology. The quality and potential of Dr. Schneck's scientific work has been well recognized with excellent support from granting agencies including Dr. Schneck leading a team of investigators that were awarded a $12 million grant in 2009, the largest basic science immunology grant in the history of Johns Hopkins University. Dr. Schneck has more than 200 scientific publications and is an inventor on several dozen submitted and granted patents.

"It is terrific to work with Ken and his team on the commercial transformation of the AIM technology to a product development platform. If the products to be developed by NexImmune are successful in human clinical trials, I believe the AIM technology has the potential to provide a major step forward for immuno-therapy for a variety of diseases," said Dr. Schneck.

####

About NexImmune, Inc.
NexImmune is an early stage biopharmaceutical company developing novel immuno-therapeutics based on the proprietary Artificial IMmune (AIM™) nanotechnology platform. Central to the AIM™ technology are artificial Antigen Presenting Cells (aAPCs) that can be engineered to orchestrate a highly specific immune attack directed toward any foreign substance or cell type in the body. In pre-clinical studies, aAPCs have been shown to have potential utility as vaccines and therapeutic agents and can also be used for the development of diagnostic products. NexImmune is using the AIM technology platform to develop a pipeline of products to treat cancer. The company's first therapeutic will be targeted at the treatment of advanced stage melanoma.

For more information, please click here

Contacts:
NexImmune, Inc.
22 Firstfield Road
Suite 280
Gaithersburg, MD 20878
phone: 301-685-1688
website www.neximmune.com

Media Contact Information:
Faye Coggins
301-685-1688 ext.104

Copyright © Marketwire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Atomic imperfections move quantum communication network closer to reality June 25th, 2017

Research accelerates quest for quicker, longer-lasting electronics: UC Riverside-led research makes topological insulators magnetic well above room temperatures June 25th, 2017

U.S. Air Force Research Lab Taps IBM to Build Brain-Inspired AI Supercomputing System: Equal to 64 million neurons, new neurosynaptic supercomputing system will power complex AI tasks at unprecedented speed and energy efficiency June 23rd, 2017

Rice U. chemists create 3-D printed graphene foam June 22nd, 2017

Nanomedicine

Researchers developed nanoparticle based contrast agent for dual modal imaging of cancer June 21st, 2017

Learning with light: New system allows optical “deep learning”: Neural networks could be implemented more quickly using new photonic technology June 12th, 2017

Mussels add muscle to biocompatible fibers: Rice University chemists develop hydrogel strings using compound found in sea creatures June 9th, 2017

Making vessels leaky on demand could aid drug delivery:Rice University scientists use magnets and nanoparticles to open, close gaps in blood vessels June 8th, 2017

Announcements

Atomic imperfections move quantum communication network closer to reality June 25th, 2017

Research accelerates quest for quicker, longer-lasting electronics: UC Riverside-led research makes topological insulators magnetic well above room temperatures June 25th, 2017

U.S. Air Force Research Lab Taps IBM to Build Brain-Inspired AI Supercomputing System: Equal to 64 million neurons, new neurosynaptic supercomputing system will power complex AI tasks at unprecedented speed and energy efficiency June 23rd, 2017

Rice U. chemists create 3-D printed graphene foam June 22nd, 2017

Patents/IP/Tech Transfer/Licensing

Aculon Expands NanoProof® Product Line for Electronics Waterproofing Technology: With growing market opportunities Aculon Launches NanoProof® 8 with Push Through Connectivity™ and NanoProof® DAB a syringe application May 30th, 2017

NREL’s Advanced Atomic Layer Deposition Enables Lithium-Ion Battery Technology: May 10th, 2017

Forge Nano 2017: 1st Quarter Media Update April 20th, 2017

Making Batteries From Waste Glass Bottles: UCR researchers are turning glass bottles into high performance lithium-ion batteries for electric vehicles and personal electronics April 19th, 2017

Appointments/Promotions/New hires/Resignations/Deaths

Nanometrics Announces Retirement Plans of CEO Timothy Stultz: Dr. Stultz to Continue as Director May 25th, 2017

180 Degree Capital Corp. Announces the Start of Kevin Rendino as Chairman and Chief Executive Officer and Completion of its Transition to a Registered Closed-End Fund March 31st, 2017

Francis Alexander Named Deputy Director of Brookhaven Lab's Computational Science Initiative February 16th, 2017

Nanobiotix appoints senior executive from pharmaceutical industry, as Chief Operating Officer: Oncology industry veteran to oversee operations and product commercialization February 8th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project